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Abstract
Background: There is limited data available on the environmental and public health impact of the
microbiological hazards associated with sputa from patients with cystic fibrosis [CF]. Pseudomonas
aeruginosa, Burkholderia cenocepacia (formerly Burkholderia cepacia genomovar III), Staphylococcus aureus and
Stenotrophomonas maltophilia are bacterial pathogens which are commonly found in the sputum of CF
patients. A study was performed to ascertain the amount of sputum produced relating to microbial loading,
as well as the diversity of bacteria present in a population of adult patients, with particular attention to
pathogenic organisms.
Methods: Sputum from adult [>18 years old] CF patients [n = 20], chosen randomly from a population
of 138 CF patients, was collected over a 24 h period on admission to the in-patient CF unit and
enumerated quantitatively, as well as the sputa from 138 adult CF patients was examined qualitatively for
the presence of infecting microflora. In addition, all different phenotypes from the sputum of each patient
were identified phenotypically employing a combination of conventional identification methods [e.g.
oxidase], as well as the API Identification schemes [API 20 NE, API 20 E].
Results: This study demonstrated that patients with cystic fibrosis generate large numbers of bacteria in
their sputum, approximating to 109 organisms per patient per day. Although these organisms are
introduced to the environment from the respiratory tract mainly via sputum, relatively few represent true
bacterial pathogens and therefore are not clinically important to the general public who are
immunocompotent. The greatest risk of such environmental microbial loading is to other patients with CF
and therefore CF patients should be made aware of the hazards of acquiring such organisms from the
environment, as well as socializing with other CF patients with certain transmissible types, such as
Pseudomonas aeruginosa and Burkholderia cenocepacia.
Conclusions: Environmental health professionals should therefore be aware that CF patients are a
greater risk to their peer grouping rather than to the general public or health care workers and that good
personal hygiene practices with CF patients should be encouraged to minimize environmental
contamination and potential acquistion.
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Introduction
Cystic fibrosis [CF] is the most commonly inherited dis-
ease in persons originating from a white and European
background, currently affecting approximately 30,000
adults and children in the US [1]. The defective gene car-
rying the mutation is carried in one in every 31 Americans
[one in 28 Caucasians], equating to more than 10 million
people being a symptomless carrier of the defective gene
[1]. It is an autosomal recessive condition whereby two
alleles carrying a polymorphism in the cystic fibrosis
transmembrane conductance regulator [CFTR] gene phe-
notypically manifest the disease state through a variety of
multiorgan problems, associated with a pharmacological
disfunction to regulate anion [chloride] secretion across
cell membranes. The most common complication of CF is
the recurrence of chronic chest infections usually caused
by bacterial pathogens [2]. CF patients continue to suffer
from recurrent and chronic respiratory tract infections and
most of their morbidity and mortality is due to such infec-
tions throughout their life [3]. These infections are usually
dominated by Gram-negative organisms, especially by the
pseudomonads, including Pseudomonas aeruginosa, Bur-
kholderia cepacia and Stenotrophomonas maltophilia. How-
ever, with modern antibiotic management with improved
antimicrobial agents, such as the carbapenems, CF
patients have an improved survival, resulting in more
adults in employment.
One important manifestation of the CF patient's disease
morbidity is the constant presence of a cough, which gen-
erally increases in frequency during an infective pulmo-
nary exacerbation [4]. Patients with CF also need to
perform daily physiotherapy which involves a variety of
techniques designed to enhance the expectoration of spu-
tum from the lungs. Quantitative microbiology of sputum
has been included as an important endpoint in several
studies [5-8] and these have demonstrated that bacterial
loading of CF sputum is in the order 107-109 colony form-
ing units [cfu] per gram sputum [9] and that the propor-
tion of individual pathogens may vary, depending on the
microbial ecology present. To date, the majority of CF
clinics routinely monitor the microbiological status of
patients through qualitative [presence/absence] examina-
tion of sputum specimens from the patient, employing a
combination of selective and non-selective culture media
to detect which bacteria are present, so that the most
appropriate antibiotics are administered to help control
the pulmonary infection and also to avoid transmissible
respiratory pathogens spreading from person-to-person.
There is limited data available on the environmental and
public health impact of the microbiological hazards asso-
ciated with CF sputum and respiratory secretions outside
of CF, particularly on: – [i]. various patient groupings
[healthy immunocompotent individuals, immunocom-
promised patients, other CF patients], [ii]. environmental
loading and contamination, [iii]. veterinary medicine and
[iv]. food. Therefore, the main aim of this study was to
determine the mass of sputum produced on a daily basis
by adult CF patients and the range and public health sig-
nificance of the resident microflora/microbiota of sputum
in order to evaluate the infection control and environ-
mental burden due to such secretions.
Materials & Methods
Determination of mass of daily sputum production in CF 
patients
Sputum from adult [>18 years old] CF patients [n = 20],
chosen randomly from a population of 138 CF patients,
was collected over a 24 h period on admission to the in-
patient CF unit. All sputum produced by each individual
patient was collected in disposable collection containers
and was pooled and weighed on digital scales [Sartorius,
Germany], to the nearest gram, to determine total daily
mass of sputum produced per patient.
Qualitative isolation of culturable microflora in sputum
Sputum was collected immediately after a standardized
session of physiotherapy and was stored at ambient tem-
perature and was processed within 4 h from collection.
Fresh sputum [1 ml min ] was mixed with an equal mass
[1:1] of Sputasol [Oxoid SR089A, Oxoid Ltd., Poole, Eng-
land] and was incubated in a water bath at 37°C for 15
min, before further processing. Processed sputa from 138
adult CF patients attending the regional CF centre was
obtained and 20 µl were inoculated individually and
incubated, onto several selective media, including: –
Columbia Blood Agar [Oxoid CM0331] supplemented
with 5% [v/v] defribinated horse blood, Chocalate Agar
[incubated microaerophilically in 5% [v/v] CO2], MacCo-
nkey Agar [Oxoid CM0007], Pseudomonas Isolation Agar
[PIA] [Oxoid CM0559 + SR0102] and Burkholderia cepacia
Selective Agar [BCSA] [MAST, MAST DM253E + SV22,
MAST Diagnostics Ltd., Merseyside, UK]. All media were
incubated aerobically at 37°C for 48 h, unless otherwise
stated. The PIA and BCSA plates were incubated at room
temperature for a further three days following initial 48
hrs incubation. In addition, all different phenotypes from
the sputum of each patient were identified phenotypically
employing a combination of conventional identification
methods [e.g. oxidase], as well as the API Identification
schemes [API 20 NE, API 20 E] [Biomérieux, Les Halles,
France].
Results and Discussion
Of the 20 adult patients examined randomly on admis-
sion, a mean value of 26.8 ± 17.8 g sputum was expecto-
rated per patient per day, with a range of 7 – 69 g.
Qualitative examination of a larger population of adult
patients [n = 138] demonstrated 25 infection/co-coloniz-Annals of Clinical Microbiology and Antimicrobials 2004, 3 http://www.ann-clinmicrob.com/content/3/1/8
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ing patterns in 122 adult patients [Table 1], with 16
[11.3%] patients exhibiting no significant microbiologi-
cal findings. Pseudomonas aeruginosa and Burkholderia cepa-
cia complex [BCC] organisms were the most commonly
isolated CF pathogens, occurring in 47.1% and 22.5%
patients, respectively. Yeasts and filamentous fungi were
isolated from 11/138 [8.0%] patients. No pneumococci
[Streptococcus pneumoniae],  Mycobacterium tuberculosis,
Pneumocystis jiroveci or  Legionella pneumophila were iso-
lated from any of the patients. Additionally, Staphylococcus
aureus was isolated from the sputum of 25/138 patients
[18.1%]. Previously we have shown in our CF centre that
quantitative microbiology on patients' sputum had a
mean cell density of 8.25 ± 0.85 log cfu g-1 sputum and a
range of 5.91 – 9.74 log cfu g-1 sputum [Moore et al.,
unpublished data]. Therefore, theoretically, by consider-
ing the mean values obtained, each CF patient may poten-
tially transfer 4.77 billion [4.77 × 109; log10 9.68 colony
forming units [cfu]] organisms per day to the environ-
ment, particularly at the onset of an infective pulmonary
exacerbation.
Although CF is the most commonly inherited disease, rel-
atively little is known about the manifestations and mor-
bidity of this disease outside of the CF community, which
has led to confusion regarding the transmissibility of CF
respiratory bacterial pathogens to the general public,
through coughing and expectorating sputum. Our study
demonstrated the infrequent isolation of bacterial patho-
gens, which are commonly associated with respiratory
tract infections with the immunocompotent population.
However, the study demonstrated the presence of Morex-
ella catarrhalis and Haemophilus influenzae in a small pro-
portion of patients examined, namely in one and two
patients, respectively. These pathogens are more com-
monly seen in non-CF patients with chest infections. Con-
sequently, even though the microbial burden generated
by CF patients is large, the types of colonizing organisms
of the CF lungs do not generally represent a significant
cross-infection risk with members of the general public or
to veterinary medicine, which can be minimized through
good personal hygiene of the CF patient. The greatest
health risk of such secretions is to other CF patients partic-
ularly in relation to the transmission of Pseudomonas aeru-
ginosa  and  Burkholderia  cepacia either directly from
patient-to-patient or indirectly via environmental con-
tamination. Hence, any exposure of CF patients to the res-
piratory secretions of other CF patients should be
avoided, including sharing of communal toothbrushes,
cutlery at mealtimes and all respiratory equipment [e.g.
Table 1: Microbiological co-colonizing/infection patterns isolated from the sputum of 138 adult patients with cystic fibrosis
Microflora/Microbiota present Number of patients Percentage of adult CF population
Pseudomonas aeruginosa 50 36.2
Burkholderia cenocepacia 17 12.3
Staphylococcus aureus 14 10.1
Pseudomonas aeruginosa &Staphylococcus aureus 75 . 1
Stenotrophomonas maltophilia 53 . 6
Pseudomonas aeruginosa &Burkholderia cenocepacia 42 . 9
Burkholderia multivorans 32 . 2
Candida sp. 32 . 2
Burkholderia cenocepacia &Staphylococcus aureus 21 . 5
Candida sp. &Burkholderia cenocepacia 21 . 5
Aspergillus sp. &Pseudomonas aeruginosa 21 . 5
Pseudomonas fluorescens 10 . 7
Aspergillus sp. 1 0.7
Commensals 1 0.7
E. coli 10 . 7
Haemophilus influenzae 10 . 7
Haemophilus parainfluenzae 10 . 7
Moraxella catarrhalis 10 . 7
Morganella morganii 10 . 7
Neiserria sp. 1 0.7
Aspergillus sp. &Staphylococcus aureus 10 . 7
Candida sp. &Pseudomonas aeruginosa 10 . 7
Haemophilus influenzae &Burkholderia cenocepacia 10 . 7
Staphylococcus aureus &Burkholderia cenocepacia &Pseudomonas aeruginosa 10 . 7
Candida sp. &Burkholderia cenocepacia &Pseudomonas aeruginosa 10 . 7
No significant growth 16 11.3Annals of Clinical Microbiology and Antimicrobials 2004, 3 http://www.ann-clinmicrob.com/content/3/1/8
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nebulizers, oxygen equipment, etc.]. Environmental
health professionals should be aware of the recently pub-
lished guidelines entitled "Infection control recommenda-
tions for patients with cystic fibrosis: Microbiology, important
pathogens, and infection control practices to prevent patient-to-
patient transmission" [10], which describe how to mini-
mize the transmission of infections amongst CF patient,
particularly where the environment acts as reservoir of
such CF pathogens.
Although there is no evidence in the literature to suggest
that CF patients, who are chronically infected with Staphy-
lococcus aureus, are at greater risk of acquiring more fre-
quent episodes of gastroenteritis due to enterotoxigenic
staphylococcal food-poisoning, there is a theoretical
increased risk of its occurrence due to the high cell density
of coagulase-positive staphylococci in respiratory secre-
tions. Of particular concern is the situation where CF
patients with chronic Staphylococcus aureus pulmonary
infection, work or are involved in commercial food pro-
duction or catering activities, particularly involving
"ready-to-eat" [RTE] foodstuffs. Most concern in the food
industry relates to the carriage of gastrointestinal bacterial
pathogens including Salmonella and Campylobacter in the
gut of production personnel. However, CF patients
present an unusual scenario in that their respiratory tract
is loaded with organisms, which is not the case in non-CF
patients. Therefore, careful consideration should be given
in terms of applying HACCP principles to this particular
group of patients. Although various HACCP type II con-
trols measures can be adopted to minimize the potential
of transfer of organism to RTE foodstuffs, including the
wearing of face masks, increased hand washing, such con-
trols are not absolute. Therefore, it may be prudent for CF
patients who are known to be positive for Staphylococcus
aureus to avoid the handling of RTE foodstuffs in commer-
cial operations and to pay particular attention to food
hygiene in the domestic setting. In any case, it is particu-
larly important to assess infected patients and the circum-
stances of each case, including type of employment,
provision of sanitation facilities at work and standards of
personal hygiene. For example, an infected food handler
with CF whose work involves touching unwrapped foods
to be consumed raw or without further cooking represents
a greater risk than an infected CF patient working in the
dispatch area of a food manufacturer.
In conclusion, patients with cystic fibrosis generate large
numbers of bacteria in their sputum, approximating to
1012  organisms per patient per year. Although these
organisms are introduced to the environment from the
respiratory tract mainly via sputum, relatively few repre-
sent true bacterial pathogens and therefore are not clini-
cally important to the general public who are
immunocompotent. The greatest risk of such environ-
mental microbial loading is to other patients with CF and
therefore CF patients should be made aware of the haz-
ards of acquiring such organisms from the environment,
as well as socializing with other CF patients with certain
transmissible types, such as Pseudomonas aeruginosa and
Burkholderia cenocepacia. Infection control healthcare pro-
fessionals should therefore be aware that CF patients are a
greater risk to their peer grouping rather than to the gen-
eral public, through the production of large quantities of
sputum and that good personal hygiene practices should
be encouraged to minimize environmental contamina-
tion. Further guidance on infection control practices is
available [11-13].
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